Procept Biorobotics Corp (PRCT) FinancialsPRCTFinancialProcept Biorobotics Corp

PROCEPT BioRobotics Corporation (PRCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hand pieces and other consumables, accounting for 58.4% of total sales, equivalent to $55.20M. Other significant revenue streams include System sales and rentals and Service. Understanding this composition is critical for investors evaluating how PRCT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, PROCEPT BioRobotics Corporation maintains a gross margin of 66.01%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -28.98%, while the net margin is -28.42%. These profitability ratios, combined with a Return on Equity (ROE) of -30.24%, provide a clear picture of how effectively PRCT converts its operational activities into shareholder value.

In the context of the broader market, PRCT competes directly with industry leaders such as BVS and IRMD. With a market capitalization of $1.24B, it holds a leading position in the sector. When comparing efficiency, PRCT's gross margin of 66.01% stands against BVS's 68.29% and IRMD's 74.07%. Such benchmarking helps identify whether PROCEPT BioRobotics Corporation is trading at a premium or discount relative to its financial performance.

Procept Biorobotics has shown revenue growth, with Q2 2026 revenue at $94.5 million, a 19% year-over-year increase. However, the company has been reporting consistent net losses, with a net loss of $26.86 million in Q2 2026 and a trailing twelve-month net loss of $109.8 million.